Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9)
To describe the yearly progression rate of atrophic lesions in the retrospective Progression of Stargardt Disease study. Read More…
Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6
To estimate the yearly rate of change of best-corrected visual acuity (BCVA) and the risk of loss 1 line or more over 1 year and to identify risk factors for BCVA loss in patients with Stargardt disease (STGD1). Read More…
Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) StudyReport No. 7
These findings suggest microperimetry allows a more comprehensive assessment of the function of the central retina, and it may serve as an outcome measure in future clinical trials for Stargardt disease and other macular diseases. Read More…
Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) StudyReport No. 5
To examine the incidence of atrophic lesions in patients with Stargardt disease. Read More…
Metrics and Acquisition Modes for Fixation Stability as a Visual Function Biomarker
To compare different metrics and acquisition modes of fixation stability as a new visual function biomarker in a large cohort of patients with ABCA4-related Stargardt disease from the multicenter prospective ProgStar study. Read More…
Progression of Visual Acuity and Fundus Autofluorescence in Recent-Onset Stargardt Disease: ProgStar Study Report #4
To investigate the impact of areas of decreased fundus autofluorescence (AF) on visual acuity (VA) in molecularly confirmed Stargardt disease (STGD1) with recent symptom onset, and investigate the association between these structural and functional measures over time. Read More…
ProgStar at ARVO 2017
The ProgStar studies will be discussed during the 2017 annual meeting of the Association for Research in Vision and Opthalmology (ARVO) from 7-11 May 2017 in Baltimore, Maryland. One Read More…
Fixation Location and Stability Using the MP-1 Microperimeter in Stargardt Disease : ProgStar Report No. 3
To determine fixation location and fixation stability in Stargardt disease (STGD1) and their association with best-corrected visual acuity (BCVA). Read More…
Visual Acuity Loss and Associated Risk Factors in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2)
To examine the association between characteristics of Stargardt disease and visual acuity (VA), to estimate the longitudinal rate of VA loss, and to identify risk factors for VA loss. Read More…
Comparison of Short-Wavelength Reduced-Illuminance and Conventional Autofluorescence Imaging in Stargardt Macular Dystrophy
To compare grading results between short-wavelength reduced-illuminance and conventional autofluorescence imaging in Stargardt macular dystrophy. Read More…
ProgStar at ARVO 2016
The ProgStar studies will be discussed during the 2016 annual meeting of the Association for Research in Vision and Opthalmology (ARVO) from 1-5 May 2016 in Seattle, Washington. Four Read More…
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1..
To describe the design and baseline characteristics of patients enrolled into 2 natural history studies of Stargardt disease (STGD1). Read More…
ProgStar at the American Society of Retina Specialists (ASRS) annual meeting
Dr. Scholl and Dr. Strauss presented ProgStar results at the ASRS annual meeting, held in July 2015 in Vienna, Austria. Read More…
ProgStar at the Royal College of Ophthalmologists Annual Congress
Dr. Strauss presented at the Royal College of Ophthalmologists Annual Congress, on 19 May 2015 in Liverpool, UK. Read More…
ProgStar at Retinal Gene Therapy Conference
The ProgStar studies were discussed during the 2015 2nd annual Retinal Gene Therapy Conference hosted by the Casey Eye Institute, on 8 May 2015 in Denver, Colorado. Read More…
ProgStar at the Austrian Ophthalmological Society
Dr. Strauss presented at the 56th Annual Meeting of the Austrian Ophthalmological Society. Read More…
ProgStar at ARVO 2015
ProgStar authors were represented at this year’s Association for Research in Vision and Opthalmology (ARVO) annual meeting in Denver, Colorado on May 3-7, 2015. Read More…
ProgStar at the Macula Society
The ProgStar study was discussed during the 2015 Annual Macula Society Meeting held 25-28 February 2015 in Scottsdale, Arizona. Read More…
Stargardt Disease: Research Advances
The Foundation Fighting Blindness has released a publication of the latest research findings for Stargardt disease treatments in the Winter, 2014 edition of Stargardt Disease: Research Advances. Read More…
In Focus: Dr. Hendrik Scholl
From the Spring 2013 issue of In Focus magazine, Dr. Hendrik Scholl’s past and future work is highlighted, along with the role of
cutting edge retinal-imaging technologies in current research. Read More…
Blog Entry: Proving A Vision-Saving Treatment Works
The Foundation Fighting Blindness’ Chief Research Officer, Dr. Steve Rose, has blogged about the community’s excitement about the ProgStar studies. Read More…
PRESS RELEASE: Stargardt Disease Natural History Study Will Help Prepare for Future Clinical Trials
The Foundation Fighting Blindness Clinical Research Institute issued a press release on September 4, 2012 announcing and describing the study. Read More…